A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-1701 Administered Orally as Single Doses to Healthy Subjects

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-1701 Administered Orally as Single Doses to Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2016

At a glance

  • Drugs IW 1701 (Primary)
  • Indications Cardiovascular disorders
  • Focus Adverse reactions
  • Sponsors Ironwood Pharmaceuticals
  • Most Recent Events

    • 23 Apr 2016 Status changed from recruiting to completed.
    • 18 Feb 2016 According to an Ironwood Pharmaceuticals media release, the company announced positive top-line data of IW-1701 for cardiovascular disease from this study.
    • 03 Nov 2015 Results are expected to be reported in the first half of 2016, according to an Ironwood Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top